Form D · Other Technology
GRO Biosciences Inc.
Cambridge, MA · CIK 0001715412
Offering snapshot reported Jul 25, 2024 · SEC filing
- Reported sold
- $27.4M Offering amount: $60.4M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 18, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 25, 2024 | Initial | $27,440,115 | No comparison | 13 | SEC filing |
| Mar 22, 2019 | Initial | $3,749,998 | No comparison | 10 | SEC filing |
| Sep 21, 2017 | Amendment | $2,099,998 | $0vs Aug 30, 2017 | 8 | SEC filing |
| Aug 30, 2017 | Initial | $2,099,998 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-519741
Source: Form D, filed Jul 25, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dan Becker | Director |
| Bruce Beutel | Director |
| Kevin Bitterman | Director |
| Rakhshita Dhar | Director |
| Ming Fang | Director |
| Christopher Gregg | Director |
| Tracey Lodie | Executive |
| Daniel J Mandell | Director, Executive |
| Dainel Mandell | Director, Executive |
| Geoffrey Smith | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
750 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139